Item 5.07 Submission of Matters to a Vote of Security Holders.

Gilead Sciences, Inc. (the "Company") held its 2022 annual meeting of
stockholders (the "Annual Meeting") in a virtual-only format on May 4, 2022. Of
the 1,255,786,961 shares of the Company's common stock entitled to vote at the
Annual Meeting, 1,082,867,413 shares were represented at the meeting in person
or by proxy, constituting a quorum. The voting results are presented below.



The Company's stockholders elected nine directors to serve for the next year and
until their successors are elected and qualified, or until their earlier death,
resignation or removal. The votes regarding the election of directors were

as
follows:



                                                                                                  Broker
Name                                      Votes For        Votes Against      Abstentions        Non-Votes

Jacqueline K. Barton, Ph.D.               939,364,402         9,837,381          3,152,581       130,513,049
Jeffrey A. Bluestone, Ph.D.               940,591,094         7,984,756          3,778,514       130,513,049
Sandra J. Horning, M.D.                   928,503,191         20,706,321   

     3,144,852       130,513,049
Kelly A. Kramer                           933,497,210         15,260,783         3,596,371       130,513,049
Kevin E. Lofton                           895,752,249         52,581,063         4,021,052       130,513,049
Harish Manwani                            918,831,812         29,962,105         3,560,447       130,513,049
Daniel P. O'Day                           871,823,865         71,402,651         9,127,848       130,513,049
Javier J. Rodriguez                       937,741,694         10,774,544         3,838,126       130,513,049
Anthony Welters                           912,548,682         35,140,086         4,665,596       130,513,049

The Company's stockholders ratified the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2022. The proposal received the following votes:





Votes For         1,020,875,369
Votes Against        60,552,677
Abstentions           1,439,367





The Company's stockholders approved, on an advisory basis, the compensation of
the Company's named executive officers as presented in the Proxy Statement. The
proposal received the following votes:



Votes For            875,824,762
Votes Against         74,354,069
Abstentions            2,175,533
Broker Non-Votes     130,513,049

The Company's stockholders approved the Gilead Sciences, Inc. 2022 Equity Incentive Plan. The proposal received the following votes:





Votes For            864,559,390
Votes Against         85,850,671
Abstentions            1,944,303
Broker Non-Votes     130,513,049










The Company's stockholders did not approve a stockholder proposal requesting
that the board of directors of the Company (the "Board") adopt a policy that the
Chairperson of the Board be an independent director. The proposal received

the
following votes:



Votes For            384,168,847
Votes Against        566,110,701
Abstentions            2,074,816
Broker Non-Votes     130,513,049




The Company's stockholders did not approve a stockholder proposal requesting
that the Board include one member from the Company's non-management employees.
The proposal received the following votes:



Votes For             63,589,287
Votes Against        882,911,737
Abstentions            5,853,340
Broker Non-Votes     130,513,049

The Company's stockholders approved a stockholder proposal requesting a 10% threshold to call a special stockholder meeting. The proposal received the following votes:





Votes For            539,585,285
Votes Against        410,356,111
Abstentions            2,412,968

Broker Non-Votes 130,513,049

The Company's stockholders did not approve a stockholder proposal requesting that the Board publish a third-party review of the Company's lobbying activities. The proposal received the following votes:





Votes For            475,014,934
Votes Against        470,778,461
Abstentions            6,560,969
Broker Non-Votes     130,513,049




The Company's stockholders did not approve a stockholder proposal requesting a
Board report on oversight of risks related to anticompetitive practices. The
proposal received the following votes:



Votes For            374,011,733
Votes Against        569,683,005
Abstentions            8,659,626
Broker Non-Votes     130,513,049

Item 9.01 Financial Statements and Exhibits.






(d)    Exhibits.



Exhibit
Number     Description

10.1 Gilead Sciences, Inc. 2022 Equity Incentive Plan 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

© Edgar Online, source Glimpses